Brimonidine and Brinzolamide

SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. SIMBRINZA is a combination of brinzolamide, a carbonic anhydrase inhibitor, and brimonidine tartrate, an alpha adrenergic agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

SIMBRINZA is comprised of two components: brinzolamide (carbonic anhydrase inhibitor) and brimonidine tartrate (alpha 2 adrenergic receptor agonist). Each of these two components decreases elevated IOP. Elevated IOP is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous field loss and optic nerve damage. Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide has a peak ocular hypotensive effect occurring at 2 to 3 hours post-dosing.

The recommended dose is one drop of SIMBRINZA in the affected eye(s) three times daily. Shake well before use. SIMBRINZA ophthalmic suspension may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart. Instill one drop in the affected eye(s) three times daily.

Hypersensitivity to any component of this product. Neonates and infants (under the age of two years). Hypersensitivity SIMBRINZA is contraindicated in patients who are hypersensitive to any component of this product.

Potential for sulfonamide hypersensitivity reactions because of the brinzolamide component. Potential for corneal endothelium cell loss. Severe renal impairment may limit the metabolism of the brinzolamide component

Most common adverse reactions occurring in approximately 3% to 5% of patients included blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, eye allergy.

Oral Carbonic Anhydrase Inhibitors. High-dose Salicylate Therapy. Central Nervous System Depressants. Antihypertensives/Cardiac Glycosides. Tricyclic Antidepressants. Monoamine Oxidase (MAO) Inhibitors

Store SIMBRINZA at 2°C to 25°C (36°F to 77°F).